This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Pediatric Ophthalmology  • Strabismus  • Ophthalmological Disorders, Other  • Alert me on articles by topic

Josefin Nilsson, MD, PhD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In an editorial in the June issue of the Archives, Beauchamp¹ addressed the complicated issue of the burden that amblyopia and strabismus impose on affected individuals as well as the consequences this has on the justification of treatment and screening for these conditions. Unfortunately, Beauchamp appears to have confused treatment and screening for amblyopia, to have used available evidence in a questionable way, and to have chosen to bring forward only selected references.

Dr Beauchamp picked a utility number of 0.83 from an article on a cost-utility analysis of therapy for amblyopia² and used this number throughout the editorial as evidence for the negative impact of untreated amblyopia. However, in the very same article the following can be read: "It has been noted that the mean time trade-off utility values of individuals with visual loss due to multiple ocular diseases decrease in direct proportion to . . . [Full Text of this Article]

AUTHOR INFORMATION